JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Insulet Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

255.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

254.88

Max

260.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

65M

88M

Pardavimai

57M

706M

P/E

Sektoriaus vid.

79.33

90.422

Pelno marža

12.403

Darbuotojai

3,900

EBITDA

90M

160M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+44.48% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.3B

19B

Ankstesnė atidarymo kaina

255.59

Ankstesnė uždarymo kaina

255.59

Naujienos nuotaikos

By Acuity

50%

50%

147 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Insulet Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2026-02-02 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026-02-02 23:38; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2026-02-02 23:28; UTC

Rinkos pokalbiai

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2026-02-02 23:23; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2026-02-02 22:57; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 22:22; UTC

Įsigijimai, susijungimai, perėmimai

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2026-02-02 22:08; UTC

Rinkos pokalbiai

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2026-02-02 21:51; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-02 21:49; UTC

Uždarbis

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2026-02-02 21:39; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:36; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2026-02-02 21:34; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:28; UTC

Įsigijimai, susijungimai, perėmimai

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2026-02-02 21:23; UTC

Uždarbis

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2026-02-02 21:19; UTC

Uždarbis

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2026-02-02 21:17; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2026-02-02 21:17; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:10; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:08; UTC

Uždarbis

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2026-02-02 21:07; UTC

Uždarbis

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Net $608.7M >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Rev $1.41B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Adj EPS 25c >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q EPS 24c >PLTR

2026-02-02 20:40; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Akcijų palyginimas

Kainos pokytis

Insulet Corp Prognozė

Kainos tikslas

By TipRanks

44.48% į viršų

12 mėnesių prognozė

Vidutinis 369.59 USD  44.48%

Aukščiausias 450 USD

Žemiausias 274 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Insulet Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

16

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

252.29 / 259.38Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

147 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat